Literature DB >> 26526068

Molecular detection of pancreatic neoplasia: Current status and future promise.

Shounak Majumder1, Suresh T Chari1, David A Ahlquist1.   

Abstract

Pancreatic cancer is usually diagnosed at an advanced stage and curative resection is feasible in only a small minority of patients at the time of diagnosis. Diagnosis at an early stage is unequivocally associated with better long-term survival. Several candidate molecular markers for early detection are currently under investigation in different phases of discovery and validation. Recent advances in the technology for whole genome, methylome, ribonucleome, and proteome interrogation has enabled rapid advancements in the field of biomarker discovery. In this review we discuss the current status of molecular markers for detection of pancreatic cancer in blood, pancreatic cyst fluid, pancreatic juice and stool and briefly highlight some promising preliminary results of new approaches that have the potential of advancing this field in the near future.

Entities:  

Keywords:  Biomarkers; Early detection of cancer; Methylation; Pancreatic cancer; Pancreatic cyst fluid; Pancreatic juice; Sensitivity and specificity; Stool

Mesh:

Substances:

Year:  2015        PMID: 26526068      PMCID: PMC4616215          DOI: 10.3748/wjg.v21.i40.11387

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  61 in total

Review 1.  Demographics, epidemiology, and inheritance of pancreatic ductal adenocarcinoma.

Authors:  Theresa Pluth Yeo
Journal:  Semin Oncol       Date:  2014-12-09       Impact factor: 4.929

2.  The clinical utility of serum CA 19-9 in the diagnosis, prognosis and management of pancreatic adenocarcinoma: An evidence based appraisal.

Authors:  Umashankar K Ballehaninna; Ronald S Chamberlain
Journal:  J Gastrointest Oncol       Date:  2012-06

3.  Diagnosing pancreatic cancer using methylation specific PCR analysis of pancreatic juice.

Authors:  Noriyoshi Fukushima; Kimberly M Walter; Takashi Uek; Norihiro Sato; Hiroyuki Matsubayashi; John L Cameron; Ralph H Hruban; Marcia Canto; Charles J Yeo; Michael Goggins
Journal:  Cancer Biol Ther       Date:  2003 Jan-Feb       Impact factor: 4.742

4.  Recurrent GNAS mutations define an unexpected pathway for pancreatic cyst development.

Authors:  Jian Wu; Hanno Matthaei; Anirban Maitra; Marco Dal Molin; Laura D Wood; James R Eshleman; Michael Goggins; Marcia I Canto; Richard D Schulick; Barish H Edil; Christopher L Wolfgang; Alison P Klein; Luis A Diaz; Peter J Allen; C Max Schmidt; Kenneth W Kinzler; Nickolas Papadopoulos; Ralph H Hruban; Bert Vogelstein
Journal:  Sci Transl Med       Date:  2011-07-20       Impact factor: 17.956

Review 5.  Systematic review of carbohydrate antigen (CA 19-9) as a biochemical marker in the diagnosis of pancreatic cancer.

Authors:  K S Goonetilleke; A K Siriwardena
Journal:  Eur J Surg Oncol       Date:  2006-11-09       Impact factor: 4.424

6.  Aberrant methylation of CpG islands in intraductal papillary mucinous neoplasms of the pancreas.

Authors:  Norihiro Sato; Takashi Ueki; Noriyoshi Fukushima; Christine A Iacobuzio-Donahue; Charles J Yeo; John L Cameron; Ralph H Hruban; Michael Goggins
Journal:  Gastroenterology       Date:  2002-07       Impact factor: 22.682

Review 7.  miRNAs in human cancer.

Authors:  Thalia A Farazi; Jessica I Spitzer; Pavel Morozov; Thomas Tuschl
Journal:  J Pathol       Date:  2010-11-18       Impact factor: 7.996

8.  Analysis of serum exosomal microRNAs and clinicopathologic features of patients with pancreatic adenocarcinoma.

Authors:  Risheng Que; Guoping Ding; Jionghuang Chen; Liping Cao
Journal:  World J Surg Oncol       Date:  2013-09-04       Impact factor: 2.754

9.  Aberrant methylation of suppressor of cytokine signalling-1 (SOCS-1) gene in pancreatic ductal neoplasms.

Authors:  N Fukushima; N Sato; F Sahin; G H Su; R H Hruban; M Goggins
Journal:  Br J Cancer       Date:  2003-07-21       Impact factor: 7.640

10.  Serum cytokine biomarker panels for discriminating pancreatic cancer from benign pancreatic disease.

Authors:  Victoria E Shaw; Brian Lane; Claire Jenkinson; Trevor Cox; William Greenhalf; Christopher M Halloran; Joseph Tang; Robert Sutton; John P Neoptolemos; Eithne Costello
Journal:  Mol Cancer       Date:  2014-05-20       Impact factor: 27.401

View more
  11 in total

1.  LOX and ACSL5 as potential relapse markers for pancreatic cancer patients.

Authors:  Weidong Ma; Ting Li; Si Wu; Jian Li; Xiuchao Wang; Hui Li
Journal:  Cancer Biol Ther       Date:  2019-02-03       Impact factor: 4.742

2.  Weighted gene co-expression network analysis reveals key genes involved in pancreatic ductal adenocarcinoma development.

Authors:  Matteo Giulietti; Giulia Occhipinti; Giovanni Principato; Francesco Piva
Journal:  Cell Oncol (Dordr)       Date:  2016-05-30       Impact factor: 6.730

3.  Overexpression of Topoisomerase 2-Alpha Confers a Poor Prognosis in Pancreatic Adenocarcinoma Identified by Co-Expression Analysis.

Authors:  Zhou Zhou; Shi Liu; Meng Zhang; Rui Zhou; Jing Liu; Ying Chang; Qiu Zhao
Journal:  Dig Dis Sci       Date:  2017-08-16       Impact factor: 3.199

Review 4.  Is metastatic pancreatic cancer an untargetable malignancy?

Authors:  Hampig Raphael Kourie; Joseph Gharios; Fadi Elkarak; Joelle Antoun; Marwan Ghosn
Journal:  World J Gastrointest Oncol       Date:  2016-03-15

5.  Identification of candidate miRNA biomarkers for pancreatic ductal adenocarcinoma by weighted gene co-expression network analysis.

Authors:  M Giulietti; G Occhipinti; G Principato; F Piva
Journal:  Cell Oncol (Dordr)       Date:  2017-02-15       Impact factor: 6.730

6.  APC promoter is frequently methylated in pancreatic juice of patients with pancreatic carcinomas or periampullary tumors.

Authors:  Mireia M Ginesta; Zamira Vanessa Diaz-Riascos; Juli Busquets; Núria Pelaez; Teresa Serrano; Miquel Àngel Peinado; Rosa Jorba; Francisco Javier García-Borobia; Gabriel Capella; Joan Fabregat
Journal:  Oncol Lett       Date:  2016-07-15       Impact factor: 2.967

7.  Islet inflammation and ductal proliferation may be linked to increased pancreatitis risk in type 2 diabetes.

Authors:  Belinda Schludi; Abu Saleh Md Moin; Chiara Montemurro; Tatyana Gurlo; Aleksey V Matveyenko; David Kirakossian; David W Dawson; Sarah M Dry; Peter C Butler; Alexandra E Butler
Journal:  JCI Insight       Date:  2017-07-06

8.  Metabolic biomarker signature to differentiate pancreatic ductal adenocarcinoma from chronic pancreatitis.

Authors:  Julia Mayerle; Holger Kalthoff; Regina Reszka; Beate Kamlage; Erik Peter; Bodo Schniewind; Sandra González Maldonado; Christian Pilarsky; Claus-Dieter Heidecke; Philipp Schatz; Marius Distler; Jonas A Scheiber; Ujjwal M Mahajan; F Ulrich Weiss; Robert Grützmann; Markus M Lerch
Journal:  Gut       Date:  2017-01-20       Impact factor: 23.059

Review 9.  Proteomic biomarkers in body fluids associated with pancreatic cancer.

Authors:  Cristina Jimenez-Luna; Carolina Torres; Raul Ortiz; Carmelo Dieguez; Joaquina Martinez-Galan; Consolacion Melguizo; Jose C Prados; Octavio Caba
Journal:  Oncotarget       Date:  2018-03-27

10.  Metabolomic biomarkers of pancreatic cancer: a meta-analysis study.

Authors:  Khyati Y Mehta; Hung-Jen Wu; Smrithi S Menon; Yassi Fallah; Xiaogang Zhong; Nasser Rizk; Keith Unger; Mark Mapstone; Massimo S Fiandaca; Howard J Federoff; Amrita K Cheema
Journal:  Oncotarget       Date:  2017-08-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.